best casino sites 0

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

http://www.morphing-aircraft.com/articles/biogen-ceo-to-step-aside-after-alzheimers-drug-struggles-11651580472

Share

Biogen CEO Michel Vounatsos to Step Aside After Alzheimer’s Drug Struggles

Company says it will eliminate the sales infrastructure for Aduhelm, saving $500 million annually

Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some doctors aren’t ready to prescribe it yet. Illustration: Jacob Reynolds
By Joseph Walker

Biogen Inc. is shedding Chief Executive Michel Vounatsos and effectively abandoning its high-profile Alzheimer’s disease treatment Aduhelm as it attempts to chart a best casino sites 0 course after Medicare’s devastating refusal to pay for it.

Biogen said Tuesday that Mr. Vounatsos, 60 years old, would continue to lead the company and remain on its board until a search for a best casino sites 0 CEO is completed. It also took steps that will effectively end its marketing of the Alzheimer’s drug.

To Read the Full Story

Continue reading your article with
a WSJ membership